跳到主要内容

MYRIAD GENETICS INC (MYGN) Stock Forecast 2025 - AI Price Prediction & Analysis


MYRIAD GENETICS INC (MYGN) AI Stock Price Forecast & Investment Analysis

MYRIAD GENETICS INC Stock Price Chart and Technical Analysis

Loading MYRIAD GENETICS INC interactive price chart and technical analysis...

MYRIAD GENETICS INC (MYGN) - Comprehensive Stock Analysis & Investment Research

Deep dive into MYRIAD GENETICS INC's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about MYRIAD GENETICS INC, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For MYRIAD GENETICS INC: MYRIAD GENETICS INC operates in the Life Sciences sector, making it an emerging small-cap investment.

MYRIAD GENETICS INC (Stock Symbol: MYGN) is a leading company in the Life Sciences sector , specifically operating within the In Vitro & In Vivo Diagnostic Substances industry.

The organization employs approximately 2656 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing MYRIAD GENETICS INC's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For MYRIAD GENETICS INC: With $832M in annual revenue and 24.5% net margin, the company demonstrates exceptional profitability.

Annual Revenue: $832 million generating a 24.5% net profit margin .

Market Capitalization: $674 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -0.9% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for MYRIAD GENETICS INC stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For MYRIAD GENETICS INC: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for MYRIAD GENETICS INC stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: MYRIAD GENETICS INC's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For MYRIAD GENETICS INC: Market positioning analysis based on available financial and operational metrics.

MYRIAD GENETICS INC strategically competes in the highly dynamic In Vitro & In Vivo Diagnostic Substances marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 88.0% gross margin, indicating strong pricing power and operational efficiency.

MYRIAD GENETICS INC (MYGN) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for MYRIAD GENETICS INC stock analysis.

Loading MYRIAD GENETICS INC comprehensive fundamental analysis and insider trading data...

Deep dive into MYRIAD GENETICS INC's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if MYRIAD GENETICS INC stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For MYRIAD GENETICS INC: With a P/E ratio of -8.61, the market sees the stock as potentially undervalued.

P/E Ratio -8.61x
P/B Ratio 1.74x
Market Cap $674M
EPS $-4.31
Book Value/Share $4.17
Revenue/Share $8.95
FCF/Share $0.71
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently MYRIAD GENETICS INC converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For MYRIAD GENETICS INC: An ROE of -0.9% indicates room for improvement in shareholder value creation.

ROE -0.9%
ROA -0.6%
ROIC -0.6%
Gross Margin 88.0%
Operating Margin 38.8%
Net Margin 24.5%
EBT Margin -5.0%
Tax Rate 49.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess MYRIAD GENETICS INC's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For MYRIAD GENETICS INC: A current ratio of 2.57 indicates strong liquidity.

Current Ratio 2.57x
Quick Ratio 2.23x
D/E Ratio 0.08x
Financial Leverage 1.32x
Interest Coverage -6.5x
Working Capital $184M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal MYRIAD GENETICS INC's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For MYRIAD GENETICS INC: Free cash flow of $-117M indicates cash challenges that need attention.

Operating Cash Flow $-100M
Free Cash Flow $-117M
Capital Spending $-17M
OCF Growth YoY -27.5%
FCF Growth YoY -32.8%
FCF/Sales -17.2%
CapEx/Sales 2.5%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively MYRIAD GENETICS INC uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For MYRIAD GENETICS INC: An asset turnover of 0.53x suggests room for improvement in asset utilization.

Asset Turnover 0.53x
Receivables Turnover 7.0x
Inventory Turnover 9.7x
Fixed Assets Turnover 6.2x
Days Sales Outstanding 52 days
Days Inventory 38 days
Payables Period 45 days
Cash Conversion Cycle 45 days
Understanding Financial Statement Data

What these metrics mean: Key figures from MYRIAD GENETICS INC's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For MYRIAD GENETICS INC: With annual revenue of $832M, MYRIAD GENETICS INC demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $832M
Operating Income $142M
Net Income $90M
R&D Expense $23M
SG&A Expense $83M
Cost of Goods Sold $250M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 34%
Cash & Short-term Investments 21%
Total Liabilities 24%
Short-term Debt 8%
Accounts Receivable 8%
Inventory 1%
Dividend & Shareholder Information
Shares Outstanding 93M
Growth Metrics (YoY)
EPS Growth 13.3%

Latest MYRIAD GENETICS INC Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting MYRIAD GENETICS INC (MYGN) stock price and investment outlook.

, source: The New York Times

He led Myriad Genetics, whose patents on the BRCA1 and BRCA2 genes, associated with breast cancer, were invalidated by the Supreme Court. By Neil Genzlinger Taking a DNA test for fun, then finding ...

MYRIAD GENETICS INC Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of MYRIAD GENETICS INC against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ACHV Unlock Forecast - 30 Days FREE Trial $153M -3.7x 3.7x
AWH Unlock Forecast - 30 Days FREE Trial $2M -0.5x -0.7x
AWHL Unlock Forecast - 30 Days FREE Trial $25M x x
BMRA Unlock Forecast - 30 Days FREE Trial $5M -0.8x 0.9x
BZYR Unlock Forecast - 30 Days FREE Trial $3M x x
CDIO Unlock Forecast - 30 Days FREE Trial $6M -2.3x 0.7x
CDIOW Unlock Forecast - 30 Days FREE Trial $2M x 0.5x
CLDX Unlock Forecast - 30 Days FREE Trial $1649M -10.1x 2.5x
ICCC Unlock Forecast - 30 Days FREE Trial $59M 33.7x 2.0x
IDXX Unlock Forecast - 30 Days FREE Trial $52771M 53.5x 36.2x
IMDX Unlock Forecast - 30 Days FREE Trial $82M x 8.0x
LNTH Unlock Forecast - 30 Days FREE Trial $3796M 14.0x 3.3x
MYGN Unlock Forecast - 30 Days FREE Trial $674M -8.6x 1.7x
NEOG Unlock Forecast - 30 Days FREE Trial $1211M -145.7x 0.5x
NTLA Unlock Forecast - 30 Days FREE Trial $1225M -2.6x 1.6x
OCX Unlock Forecast - 30 Days FREE Trial $81M -0.7x 7.9x
QDEL Unlock Forecast - 30 Days FREE Trial $1934M -1.6x 0.7x
TKNO Unlock Forecast - 30 Days FREE Trial $238M -8.6x 3.1x
TNFA Unlock Forecast - 30 Days FREE Trial $1M -0.2x 0.1x
VNRX Unlock Forecast - 30 Days FREE Trial $66M 2.7x -2.5x

Frequently Asked Questions - MYRIAD GENETICS INC Stock Forecast

How accurate are MYRIAD GENETICS INC stock predictions?

Our AI model demonstrates 53% historical accuracy for MYGN predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence MYRIAD GENETICS INC stock price forecasts?

Our analysis considers MYRIAD GENETICS INC's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is MYRIAD GENETICS INC a good investment in 2025?

Based on our AI analysis, MYRIAD GENETICS INC shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are MYRIAD GENETICS INC forecasts updated?

MYRIAD GENETICS INC stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced MYRIAD GENETICS INC Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for MYRIAD GENETICS INC stock.

My Portfolio

Investment Dashboard

Loading your portfolio...